SCHEMBL5536030

SCHEMBL5536030

[CH2]c1ccccc1Oc1cc(F)cc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP2A6 P11509 1/20 0.40
SLC6A4 P31645 6/20 0.36
HTR2A P28223 2/20 0.36
HTR1A P08908 4/20 0.36
SLC6A2 P23975 4/20 0.36
SLC6A3 Q01959 3/20 0.36
FFAR4 Q5NUL3 2/20 0.35
FFAR1 O14842 1/20 0.35
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.35
EPAS1 Q99814 4/20 0.34
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
VEGFA P15692 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755349 0.83 ALDH1A1 (0.49) CYP1A2SLC6A4HTR2AHTR1ASLC6A2
SCHEMBL5540892 0.82 SLC6A4 (0.37) CYP1A2SLC6A4HTR2AHTR1ASLC6A2
SCHEMBL2093908 0.78 HSPB1 (0.38) CYP1A2CYP2A6SLC6A2ALDH1A1L3MBTL1
SCHEMBL95189 0.76 LTA4H (0.52) SLC6A4HTR1ASLC6A2SLC6A3ALDH1A1
SCHEMBL9713459 0.76 CYP1A2 (0.40) CYP1A2CYP2A6SLC6A4HTR2AHTR1A
SCHEMBL5540267 0.76 ALDH1A1 (0.47) CYP1A2CYP2A6SLC6A4SLC6A2SLC6A3
SCHEMBL5540384 0.76 NPSR1 (0.56) SLC6A4HTR2AALDH1A1L3MBTL1LMNA
SCHEMBL5540166 0.76 SLC6A2 (0.42) SLC6A4SLC6A2SLC6A3
SCHEMBL10546983 0.76 PARP10 (0.42) CYP1A2CYP2A6SLC6A4HTR2AHTR1A
SCHEMBL7634253 0.75 CA1 (0.38) ALDH1A1L3MBTL1LMNAMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP1A2 659/4885CYP2A6 1119/4885SLC6A4 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.